3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Motor Activity
234
Breast Neoplasms
132
Neoplasms
97
Prostatic Neoplasms
34
Fatigue
34
Obesity
24
Lung Neoplasms
23
Colorectal Neoplasms
22
Polycystic Ovary Syndrome
17
Ovarian Neoplasms
13
Colonic Neoplasms
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Lymphoma
11
Carcinoma, Non-Small-Cell Lung
11
Weight Loss
10
Rectal Neoplasms
10
Multiple Myeloma
10
Lymphedema
10
Hematologic Neoplasms
10
Head and Neck Neoplasms
10
Leukemia
9
Insulin Resistance
8
Cardiotoxicity
8
Brain Neoplasms
8
Stomach Neoplasms
7
Peripheral Nervous System Diseases
7
Overweight
6
Esophageal Neoplasms
6
Cognitive Dysfunction
6
Interventions
Carboplatin
19
Pemetrexed
10
Paclitaxel
7
pembrolizumab
5
Nivolumab
5
Cisplatin
5
Gemcitabine
4
osimertinib
3
entinostat
3
camrelizumab
3
atezolizumab
3
Erlotinib Hydrochloride
3
zipalertinib
2
selpercatinib
2
pralsetinib
2
durvalumab
2
apatinib
2
Vinorelbine
2
Surveys and Questionnaires
2
One-Lung Ventilation
2
Ipilimumab
2
Docetaxel
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
toripalimab
1
spartalizumab
1
sotorasib
1
sitravatinib
1
sintilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lung Diseases
×
Exercise
×
Clear all
NCT04666558
2022-10-04
PiONEeR
University of Alberta
Phase NA
Completed
216 enrolled